Tapering Venlafaxine 150mg and Switching to Vortioxetine
For a patient on venlafaxine (Effexor) 150 mg who wants to switch to vortioxetine (Trintellix), gradually taper the venlafaxine by reducing the dose by 75 mg per week, then start vortioxetine at 10 mg daily after completing the taper.
Venlafaxine Tapering Protocol
The FDA label for Effexor XR explicitly states that tapering should be achieved by reducing the daily dose by 75 mg at 1-week intervals 1. This is critical because venlafaxine has a well-documented discontinuation syndrome that can cause significant distress 2.
Specific Tapering Schedule:
- Week 1: Reduce from 150 mg to 75 mg daily
- Week 2: Reduce from 75 mg to 37.5 mg daily (if available) or discontinue
- Monitor closely: If 37.5 mg formulation unavailable, the jump from 75 mg to zero may require slower tapering
Critical caveat: Venlafaxine should be tapered when discontinuing because withdrawal syndrome has been well-described 2. The guideline evidence consistently emphasizes that venlafaxine requires 2-4 weeks to titrate and similar time to taper safely 2.
Why Gradual Tapering Matters
Venlafaxine has been specifically associated with:
Research shows that alternate-day dosing during tapering risks severe withdrawal effects and cannot be recommended 4. The discontinuation syndrome can include dizziness, nausea, anxiety, and flu-like symptoms 5. While some studies suggest minimal difference between 3-day and 14-day tapers 6, this applies to switching between antidepressants, not complete discontinuation—and venlafaxine's short half-life makes gradual dose reduction more important than extended time at each dose.
Starting Vortioxetine
Once venlafaxine is fully discontinued:
- Start vortioxetine at 10 mg once daily 7
- Can be taken without regard to meals 7
- May increase to 20 mg daily as tolerated, or reduce to 5 mg if not tolerated 7
No washout period is required between venlafaxine and vortioxetine since neither is an MAOI. The FDA label for Effexor only requires 7 days after stopping venlafaxine before starting an MAOI 1, and vortioxetine is not an MAOI.
Monitoring During Transition
Watch for:
- Discontinuation symptoms: Dizziness, nausea, anxiety, irritability, sensory disturbances 5
- Worsening depression: Can occur during antidepressant discontinuation 6
- Emergent suicidal ideation: Documented risk during venlafaxine taper 6
If intolerable symptoms emerge during tapering, resume the previous dose and slow the taper rate further 1.
Clinical Rationale for This Approach
The evidence strongly supports gradual tapering over abrupt discontinuation. The FDA label provides the clearest guidance: 75 mg weekly decrements 1. This is more conservative than some research suggesting faster tapers 6, but prioritizes patient safety and tolerability—particularly important given venlafaxine's association with severe discontinuation symptoms and suicide risk 3.
Vortioxetine has demonstrated comparable efficacy to venlafaxine in head-to-head trials 8, with better tolerability and fewer discontinuation rates (18.0% vs 27.4%) 8. This makes it a reasonable alternative, though the switch should be executed carefully to avoid the well-documented risks of venlafaxine withdrawal.